| Today's Big NewsOct 24, 2022 |
|
A GPS to your next blockbuster drug - Design molecules towards your desired properties through AI+Biophysics. Learn more.
|
|
| By Zoey Becker In a case that kicked off in 2018, the husband and wife duo of Allen and Xanthe Lam were sentenced to six months of imprisonment each for stealing Genentech trade secrets and handing them off to JHL Biotech. The two were also dealt fines of more than $10,000. |
|
|
|
By Gabrielle Masson After a second patient death, Alpine Immune Sciences is terminating enrollment for two trials assessing its cancer asset davoceticept, including the biotech’s combo study with Merck’s Keytruda for adults with advanced malignancies. |
By Dave Muoio The suspect was on parole for aggravated robbery and was permitted to visit the hospital with an ankle bracelet as his girlfriend gave birth, according to the Dallas Police Department. |
By Andrea Park Barely one week into his tenure as president and CEO of Philips, Roy Jakobs is already being put to the test. |
By James Waldron A phase 3 failure puts another nail in the coffin for Tricida to get its kidney disease drug, veverimer, to market, two years after the FDA denied approval. Having already taken a battering with previous regulatory woes, Tricida’s stock price plummeted 93% in pre-market trading this morning to 65 cents. |
By Fraiser Kansteiner Late last week, AbbVie said Rinvoq had nabbed its sixth FDA nod, this time in adults with active non-radiographic axial spondyloarthritis (nr-axSpA). AbbVie has pinned big hopes on Rinvoq and its sibling Skyrizi, considering megablockbuster Humira will face biosimilars as early as January 2023. |
By Dave Muoio An early start to respiratory illness season is overwhelming pediatric facilities across the country. Clinicians warn that the situation could become worse as influenza and COVID-19 pick up with the cold weather. |
By Conor Hale The new enterprise will shepherd the medtech giant’s Puritan Bennett brand of ventilators—which had once seen wide demand during the early phases of the COVID-19 pandemic, though sales have since dramatically declined. |
By Nick Paul Taylor Novartis is coming for the jewels of AstraZeneca’s $39 billion takeover of Alexion. In a phase 3 trial, the Swiss drugmaker’s iptacopan beat the incumbent rare disease drugs Soliris and Ultomiris, advancing its plan to turn the oral challenger into a $3 billion-a-year blockbuster. |
By Fraiser Kansteiner Another vaccine manufacturing effort has kicked off in Africa, this time centered around access to low-cost measles and rubella shots. |
By Paige Minemyer Another gene therapy product is set for an FDA determination in short order, and this trend should make payers stand up and pay attention, according to experts at Optum. |
By James Waldron Gene therapy may be a hot area of biotech development, but that doesn’t mean companies are finding it any easier to navigate the bear market. These now include Applied Genetic Technologies, which, rather than face a looming “challenging” funding environment, has opted for a $23.5 million sale to investment fund Syncona. |
By Andrea Park Though only about an inch in diameter, BioIntelliSense’s BioButton wearable device for remote monitoring boasts an impressive reach—and one that’s still growing, thanks to the company’s recent acquisition of additional patient-tracking software. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about our special report on the top 10 vaccine company rankings. We also report the news on Pfizer's kickback lawsuit, OTC hearing aids and more. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now.
|
|
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
